Victory Capital Management
BDTX icon

Victory Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

Victory Capital Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10,203
Closed -$248K – 2753
2021
Q1 		$248K Sell
10,203
-567
-5% -$15.3K ﹤0.01% 2465
2020
Q4 		$345K Buy
+10,770
New +$354K ﹤0.01% 2229
2020
Q3 		– Sell
-12,737
Closed -$537K – 2498
2020
Q2 		$537K Sell
12,737
-11,107
-47% -$409K ﹤0.01% 1967
2020
Q1 		$594K Buy
+23,844
New +$726K ﹤0.01% 2031

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Victory Capital Management's BDTX Position: Q2 2021 in Review

Victory Capital Management sold out of Black Diamond Therapeutics (BDTX) in Q2 2021, closing a stake of 10,203 shares — an estimated $248K sold.

Victory Capital Management first reported a position in BDTX in Q1 2020 and held it in 4 quarters. The position peaked at $594K in Q1 2020. 102 funds tracked by Wall St. Rank hold BDTX as of Q2 2021.

  • Victory Capital Management reported no remaining Black Diamond Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Victory Capital Management sold 10,203 Black Diamond Therapeutics shares in Q2 2021, an estimated $248K.
  • Victory Capital Management first reported a position in Black Diamond Therapeutics in Q1 2020 and held it in 4 quarters.
  • Victory Capital Management's Black Diamond Therapeutics position peaked at $594K in Q1 2020.
  • 102 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2021.

Based on Victory Capital Management's 13F filing for Q2 2021, filed 3 Aug 2021.